Celltrion Prepares Aflibercept For Phase III
Follows In Footsteps Of Denosumab, Omalizumab And Ustekinumab Biosimilars
Celltrion has announced that its latest biosimilar development project is progressing to Phase III trials, with its aflibercept rival to Eylea following recent advances for the Korean firm’s denosumab, omalizumab and ustekinumab candidates.
